BiomX Inc. - Common stock, par value $0.0001 per share (PHGE)

Historical Holders from Q3 2019 to Q3 2025

Symbol
PHGE on NYSE
Type / Class
Equity / Common stock, par value $0.0001 per share
Shares outstanding
27,615,000
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
97,025
Holdings value
$50,938
Number of holders
2
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of BiomX Inc. - Common stock, par value $0.0001 per share (PHGE)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Flynn James E 9.99% $11,359,221 15,558,445 Deerfield Management Company, L.P. 27 Feb 2025
Cystic Fibrosis Foundation 9.99% -50% $1,820,950 -$887,608 2,494,110 -39% Cystic Fibrosis Foundation 27 Feb 2025
OrbiMed Israel BioFund GP Limited Partnership 1% 276,150 ORBIMED ISRAEL GP LTD. 18 Jun 2025

Institutional Holders of BiomX Inc. - Common stock, par value $0.0001 per share (PHGE)

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 97,025 $50,938 $0.5235 2
2025 Q2 97,025 $42,693 $0.4464 2
2025 Q1 97,025 $53,916 +$88 $0.5546 2
2024 Q4 96,866 $70,722 -$180,485 $0.7301 1
2024 Q3 300,942 $306,960 -$9,565,298 $1.02 2
2024 Q2 23,249,529 $7,814,136 +$3,181,319 $0.3361 11
2024 Q1 13,770,839 $6,196,607 +$2,595,251 $0.45 9
2023 Q4 8,090,280 $2,264,622 -$123,935 $0.28 13
2023 Q3 7,452,452 $2,623,356 -$89,854 $0.352 10
2023 Q2 7,707,696 $2,773,941 +$508,057 $0.36 10
2023 Q1 6,330,423 $1,930,752 +$60,644 $0.305 13
2022 Q4 6,162,512 $1,150,412 -$38,943 $0.1867 14
2022 Q3 6,157,008 $2,094,000 -$3,300 $0.3404 14
2022 Q2 6,178,650 $4,511,000 -$860,155 $0.7302 11
2022 Q1 6,615,338 $12,767,000 +$118,115 $1.93 13
2021 Q4 6,557,269 $10,492,000 -$754,303 $1.6 13
2021 Q3 6,951,985 $21,271,508 +$2,591,965 $3.06 18
2021 Q2 6,092,788 $33,266,828 -$586,998 $5.46 14
2021 Q1 6,181,431 $44,013,000 -$199,941 $7.12 14
2020 Q4 4,141,611 $26,423,000 +$240,908 $6.38 9
2020 Q3 6,223,539 $39,457,000 +$656,982 $6.34 10
2020 Q2 6,122,432 $33,793,000 +$406,933 $5.51 12
2020 Q1 6,035,721 $42,249,000 +$6,038,719 $7 11
2019 Q4 5,158,604 $49,961,000 +$28,282,907 $9.68 8
2019 Q3 100,141 $1,016,000 +$1,016,001 $10.15 1